Medexus Pharmaceuticals Croissance future
Future contrôle des critères 5/6
Medexus Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 52.3% et de 14.3% par an respectivement. Le BPA devrait croître de de 52.2% par an. Le rendement des capitaux propres devrait être 32% dans 3 ans.
Informations clés
52.3%
Taux de croissance des bénéfices
52.19%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 14.2% |
| Taux de croissance des recettes | 14.3% |
| Rendement futur des capitaux propres | 32.00% |
| Couverture par les analystes | Low |
| Dernière mise à jour | 26 Jun 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Jun 17
MDP: Share Repurchases And New Cell Therapy Rights Will Support Upside
Analysts have modestly adjusted their fair value price target for Medexus Pharmaceuticals stock to CA$8.00, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations, while keeping the overall valuation level unchanged. What's in the News for Medexus Pharmaceuticals Secured exclusive Canadian rights to commercialize UM171 Cell Therapy, branded as Zemcelpro (dorocubicel) in Europe, through a license and supply agreement with ExCellThera and its subsidiary Cordex Biologics.Mise à jour du récit • Jun 02
MDP: Ongoing Share Repurchases Will Support Upside Potential
Analysts have adjusted their CA$ price target on Medexus Pharmaceuticals, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E as the key drivers of the revised valuation. What's in the News Medexus reported an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, with 56 healthcare institutions having granted positive formulary inclusion decisions as of March 31, 2026, and 64 transplant centers having ordered the product for procedures.Mise à jour du récit • Apr 27
MDP: Share Repurchases And Transplant Center Adoption Will Support Upside
Analysts have modestly raised their CA$ price target on Medexus Pharmaceuticals, citing slightly higher modeled revenue growth of 21.21% and a profit margin assumption of 24.84%, while keeping the fair value and discount rate unchanged. What's in the News Medexus provided an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, including recent progress with transplant center formulary decisions and ordering activity.Mise à jour du récit • Apr 09
MDP: Share Buyback And Higher Future P E Multiple Will Support Upside
Analysts have adjusted their CA$ price target on Medexus Pharmaceuticals, citing updated assumptions around revenue growth, profit margins, and future P/E that refine their outlook on the company’s valuation. What's in the News Medexus Pharmaceuticals completed a share buyback tranche covering 191,900 shares, equal to 0.59% of its shares, between November 20, 2025 and December 31, 2025 (Key Developments).Mise à jour du récit • Mar 26
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have modestly lifted their price target on Medexus Pharmaceuticals to CA$8.00, reflecting slightly higher modeled revenue growth, a small uptick in profit margin assumptions, and a marginally lower future P/E multiple. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares from November 20, 2025 to December 31, 2025, representing 0.59% of its shares, for a total of CA$0.52 million under its previously announced buyback program (Key Developments).Mise à jour du récit • Mar 11
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have raised their CA$ price target on Medexus Pharmaceuticals, citing slightly stronger modeled revenue growth of 19.57% and a profit margin of 27.71%, along with a modestly lower forward P/E of 4.80x in their updated assumptions. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares, representing 0.59% of shares, for CAD 0.52 million under its buyback program announced on November 20, 2025 (Key Developments).Mise à jour du récit • Feb 25
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have revised their CA$ price target on Medexus Pharmaceuticals upward, reflecting updated assumptions that include modeled revenue growth of 19.35%, a profit margin of 27.36% and a slightly lower forward P/E of 4.85x. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares, representing 0.59% of its outstanding equity, for a total cost of CA$0.52 million under the buyback announced on November 20, 2025 (Key Developments).Mise à jour du récit • Feb 10
MDP: Share Repurchase Plan Will Support Higher Future Shareholder Value
Analysts have modestly adjusted their price target on Medexus Pharmaceuticals, citing updated assumptions around revenue growth of about 17.94%, profit margin of about 25.99% and a future P/E of about 5.10x. Together, these figures inform a refreshed fair value view of US$8.00 per share.Mise à jour du récit • Jan 26
MDP: Share Repurchase Plan Will Support Stronger Future Shareholder Returns
Analysts have lifted their price target on Medexus Pharmaceuticals to US$8.00 from US$8.00, citing slightly higher modeled revenue growth, a modestly stronger profit margin outlook, and a small adjustment to the future P/E assumption. What's in the News Medexus Pharmaceuticals has announced a share repurchase program that allows the company to buy back up to 2,983,650 shares, or 9.2% of its issued share capital, with all repurchased shares set to be cancelled.Mise à jour du récit • Jan 11
MDP: Share Repurchase Program Will Support Stronger Future Shareholder Returns
Analysts have reaffirmed their price target on Medexus Pharmaceuticals at US$8.00, citing updated assumptions for revenue growth, profit margins, and future P/E that adjust their overall outlook while keeping the fair value level unchanged. What's in the News Medexus Pharmaceuticals Inc.Article d’analyse • Jan 03
Does Medexus Pharmaceuticals (TSE:MDP) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Mise à jour du récit • Dec 16
MDP: Share Repurchase Program Will Drive Stronger Future Shareholder Returns
Analysts have raised their price target for Medexus Pharmaceuticals to approximately $8.00 per share from about $6.00, citing expectations of stronger revenue growth, a substantial improvement in profit margins, and a lower projected future P/E multiple that enhances the stock's valuation appeal. What's in the News Medexus Pharmaceuticals Inc.
Mise à jour du récit • Aug 20
US Transplant Centers Will Drive Specialty Care Adoption
Despite notable improvements in net profit margin and revenue growth forecasts, the consensus analyst price target for Medexus Pharmaceuticals has been revised downward from CA$7.11 to CA$6.71. What's in the News Medexus Pharmaceuticals received approval from US CMS for New Technology Add-On Payment (NTAP) reimbursement for GRAFAPEX™ (treosulfan) for Injection for fiscal year 2026.Mise à jour du récit • Aug 06
US Transplant Centers Will Drive Specialty Care Adoption
The notable increase in Medexus Pharmaceuticals' consensus price target is primarily driven by a significant rise in its future P/E valuation, with fair value revised upward from CA$6.50 to CA$7.11. Valuation Changes Summary of Valuation Changes for Medexus Pharmaceuticals The Consensus Analyst Price Target has risen from CA$6.50 to CA$7.11.Article d’analyse • May 04
Earnings Tell The Story For Medexus Pharmaceuticals Inc. (TSE:MDP) As Its Stock Soars 28%
Those holding Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares would be relieved that the share price has rebounded 28...
Nouveau récit • Feb 19
FDA Approval Of GRAFAPEX Will Unlock Market Potential With 7 Years Exclusivity
Successful FDA approval for GRAFAPEX is expected to significantly increase revenue, providing a robust new stream with its granted exclusivity.Article d’analyse • Jan 19
Investors Appear Satisfied With Medexus Pharmaceuticals Inc.'s (TSE:MDP) Prospects As Shares Rocket 52%
Despite an already strong run, Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have been powering on, with a gain of...Article d’analyse • Dec 05
After Leaping 31% Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Are Not Flying Under The Radar
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have had a really impressive month, gaining 31% after a shaky period...Article d’analyse • Nov 05
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Aug 19
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings
Medexus Pharmaceuticals Inc.'s ( TSE:MDP ) stock was strong despite it releasing a soft earnings report last week. We...Article d’analyse • Aug 10
Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Medexus Pharmaceuticals Inc. ( TSE:MDP ) just released its latest quarterly results and things are looking bullish. It...Article d’analyse • Jul 31
Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shareholders have had their patience rewarded with a 29% share price jump in...Article d’analyse • Jun 15
The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...Article d’analyse • Apr 25
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Mar 03
Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
The Medexus Pharmaceuticals Inc. ( TSE:MDP ) share price has softened a substantial 26% over the previous 30 days...Article d’analyse • Jan 06
Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have had a really impressive month, gaining 89% after a shaky period...Article d’analyse • Oct 11
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 3/31/2029 | 162 | 42 | N/A | 44 | 3 |
| 3/31/2028 | 139 | 24 | N/A | 30 | 5 |
| 3/31/2027 | 110 | 10 | N/A | 17 | 4 |
| 3/31/2026 | 99 | -2 | 4 | 19 | N/A |
| 12/31/2025 | 99 | 0 | 10 | 17 | N/A |
| 9/30/2025 | 104 | 0 | 13 | 16 | N/A |
| 6/30/2025 | 106 | 1 | 14 | 20 | N/A |
| 3/31/2025 | 108 | 2 | 21 | 24 | N/A |
| 12/31/2024 | 110 | 4 | 20 | 23 | N/A |
| 9/30/2024 | 105 | 2 | 19 | 22 | N/A |
| 6/30/2024 | 109 | 1 | 22 | 23 | N/A |
| 3/31/2024 | 113 | 0 | 18 | 19 | N/A |
| 12/31/2023 | 116 | 6 | 21 | 21 | N/A |
| 9/30/2023 | 119 | 5 | 13 | 13 | N/A |
| 6/30/2023 | 117 | 3 | 6 | 7 | N/A |
| 3/31/2023 | 108 | 1 | -2 | -1 | N/A |
| 12/31/2022 | 100 | -11 | -3 | -2 | N/A |
| 9/30/2022 | 92 | -11 | -3 | -1 | N/A |
| 6/30/2022 | 82 | 2 | 0 | 2 | N/A |
| 3/31/2022 | 77 | -3 | -9 | -1 | N/A |
| 12/31/2021 | 74 | -8 | -17 | -1 | N/A |
| 9/30/2021 | 77 | -20 | -18 | -1 | N/A |
| 6/30/2021 | 77 | -31 | -21 | -5 | N/A |
| 3/31/2021 | 80 | -28 | -6 | 5 | N/A |
| 12/31/2020 | 79 | -19 | -1 | 0 | N/A |
| 9/30/2020 | 69 | -9 | 1 | 1 | N/A |
| 6/30/2020 | 64 | -7 | 1 | 1 | N/A |
| 3/31/2020 | 56 | -5 | -3 | -2 | N/A |
| 12/31/2019 | 47 | -4 | N/A | 0 | N/A |
| 9/30/2019 | 45 | -3 | N/A | 0 | N/A |
| 6/30/2019 | 36 | -6 | N/A | -1 | N/A |
| 3/31/2019 | 25 | -5 | N/A | -1 | N/A |
| 12/31/2018 | 17 | -5 | N/A | -2 | N/A |
| 9/30/2018 | 9 | -5 | N/A | -1 | N/A |
| 6/30/2018 | 8 | -2 | N/A | -2 | N/A |
| 3/31/2018 | 8 | -3 | N/A | -3 | N/A |
| 12/31/2017 | 8 | -3 | N/A | -3 | N/A |
| 9/30/2017 | 7 | -3 | N/A | -4 | N/A |
| 6/30/2017 | 6 | -3 | N/A | -4 | N/A |
| 3/31/2017 | 5 | -1 | N/A | -1 | N/A |
| 12/31/2016 | 4 | 1 | N/A | 1 | N/A |
| 9/30/2016 | 3 | 1 | N/A | 1 | N/A |
| 6/30/2016 | 3 | 1 | N/A | 1 | N/A |
| 3/31/2016 | 3 | -2 | N/A | -1 | N/A |
| 12/31/2015 | 3 | -4 | N/A | -3 | N/A |
| 9/30/2015 | 2 | -4 | N/A | -3 | N/A |
| 6/30/2015 | 2 | -5 | N/A | -3 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: MDP devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 3% ).
Bénéfices vs marché: MDP devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.
Croissance élevée des bénéfices: MDP devrait devenir rentable dans les 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de MDP ( 14.3% par an) devrait croître plus rapidement que le marché Canadian ( 4.6% par an).
Croissance élevée des revenus: Le chiffre d'affaires de MDP ( 14.3% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de MDP devrait être élevé dans 3 ans ( 32 %)
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/28 07:52 |
| Cours de l'action en fin de journée | 2026/06/26 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Medexus Pharmaceuticals Inc. est couverte par 10 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| David Martin | Bloom Burton & Co. |